healthium medtech Strengthens cardiac care portfolio through
Exclusive india partnership With tisgenx, Inc.
Mumbai, 15th October 2025: Healthium Medtech, a global medtech company with a growing portfolio across surgical, post-surgical, advanced wound care, arthroscopy and infection prevention, has announced an exclusive partnership with US-based Tisgenx, Inc., the world’s leading manufacturer of bovine pericardial tissue patches. These patches, widely used in valve repair, vessel reconstruction and other complex cardiovascular and soft tissue interventions, are now made available to indian surgeons through this collaboration. Under this agreement, Healthium has secured exclusive multiple rights to distribute Tisgenx’s products in India.
By expanding access to proven cardiac solutions, this partnership strengthens Healthium’s position in the cardiac care segment and reinforces its commitment to innovation-led, specialty-driven offerings. Known for their superior quality and reliability, the addition of Tisgenx’s pericardial tissue patches also aligns with Healthium’s focus on delivering high-performance, surgeon-centric innovations that simplify clinical decisions and support better healthcare outcomes.
Anish Bafna, CEO & MD of Healthium Medtech, said that the collaboration enhances the company’s cardiac care offerings and reinforces its commitment to providing high-quality, best-in-class products that resonate well with Indian surgeons. “We are proud to bring Tisgenx’s globally respected pericardial tissue patches to India through this exclusive partnership. As a homegrown medtech company, we remain focused on providing solutions that address the evolving needs of Indian surgeons and support them in their effort to deliver the best care for their patients,” he commented.
Kris Kupumbati, CEO & President of Tisgenx, Inc., noted that India is a strategic market for the company and expressed confidence in Healthium’s ability to deliver clinical value. "India represents one of the fastest-growing healthcare markets in the world and this exclusive partnership with Healthium allows us to play a meaningful role in advancing cardiac care here,” he said, adding, “Together, we are strengthening local access to global innovation and reinforcing our shared commitment to surgeon-centric, patient-first solutions."
This tie-up reflects Healthium’s continued efforts to contribute to the Indian medtech ecosystem by enabling local access to global innovation. It also reinforces the company’s commitment to strengthening the broader surgical care ecosystem by delivering advanced solutions tailored to on-ground clinical needs.
About Healthium Medtech Limited:
Healthium Medtech Limited is a global medtech company focused on products in surgical, post-surgical, advanced wound care, arthroscopy and infection prevention segments. 1 in 5 surgeries conducted globally uses a Healthium product. It is the largest independent Indian medical device company and the largest non-captive manufacturer of surgical needles globally. With a vision to provide access to precision medtech for every patient globally, the company has built the nation’s largest sales force with an extensive market access in India, covering over 40,000 surgeons across 18,000 hospitals.
The company’s diverse portfolio includes 52,000 SKUs across advanced surgery, arthroscopy, wound care and infection prevention products. With a strong focus on R&D, the company has 6 high precision, integrated and scaled manufacturing facilities with global certifications and approvals like US FDA, CDSCO, TGA, ISO, cGMP, MDSAP and CE under the stringent new EUDMR norms. Healthium also has significant global presence with exports to over 90+ countries, including the USA, France, Germany and Brazil. In the last 4 years, the company has launched 35+ new products including a patented portfolio of arthroscopy products.
About Tisgenx, Inc.:
Founded in 2017, Tisgenx, Inc. is a rapidly growing medical device company specializing in advanced tissue-based solutions. In just a few years, the company’s Bovine Pericardial Tissue Patch portfolio has received both FDA and CE approvals and has been implanted in more than 40,000 patients across over 60 countries. This achievement highlights Tisgenx’s ability to deliver innovation and quality at scale, addressing complex needs in cardiothoracic, vascular, urology, and soft tissue repair and reconstruction.
Tisgenx is dedicated to advancing surgical care through innovation, accessibility and global partnerships. The company collaborates with hospitals, surgeons and distributors worldwide to provide high-performance solutions that improve outcomes and support clinical excellence. Backed by its proprietary elixP™ Tissue Technology and a rigorous commitment to safety, quality and affordability, Tisgenx has quickly established itself as a trusted global leader in tissue-based medical devices, shaping the future of medtech and expanding access to life-saving solutions.
Post a Comment